Form 4: Beam Therapeutics CFO Sells Shares for Tax Obligations

Beam Therapeutics' Chief Financial Officer, Sravan Kumar Emany, sold 6,294 shares of common stock at $27.1 per share to cover tax withholding obligations.

Summary

• Chief Financial Officer Sravan Kumar Emany of Beam Therapeutics Inc. sold 6,294 shares of common stock.
• The transaction occurred on December 31, 2025, at a price of $27.1 per share.
• The sale was non-discretionary and executed to cover tax withholding obligations related to the vesting of restricted stock units.
• These restricted stock units were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on December 30, 2022.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Emany on August 11, 2025.
• Following the transaction, Mr. Emany beneficially owns 73,706 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary sale by an insider to cover tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. It does not indicate a change in management's view of the company's prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes by an executive.

Key Dates

Recommendation

The sale of shares by the Chief Financial Officer was a non-discretionary transaction to cover tax withholding obligations upon the vesting of restricted stock units, executed under a pre-established Rule 10b5-1 trading plan. This type of transaction is routine and does not typically signal a change in the company's fundamentals or management's confidence, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Beam Therapeutics, BEAM, Form 4, Insider Trading, Stock Sale, CFO, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Equity Incentive Plan